(Q38211597)

31 August 2017

title

Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs (English)

1 reference

31 August 2017

L H Opie

1

1 reference

31 August 2017

publication date

1 August 2014

1 reference

Cardiovascular Drugs and Therapy

31 August 2017

published in

1 reference

31 August 2017

volume

28

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

331-334

1 reference

Controversies in the cardiovascular management of type 2 diabetes

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Structural state of the Na+/D-glucose cotransporter in calf kidney brush-border membranes. Target size analysis of Na+-dependent phlorizin binding and Na+-dependent D-glucose transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Urinary tract infections in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Effects of dapagliflozin on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6522-0

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD008143.PUB3

10.1007/S10557-014-6522-0

9 February 2024

Identifiers

DOI

1 reference

31 August 2017

1 reference